This is a summary of the European public assessment report (EPAR) for Zepatier. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zepatier. For practical information about using Zepatier, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1). For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.
Therapeutic Area (MeSH)
N/AATC Code
J05AP54
ATC Item
elbasvir and grazoprevir
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Zepatier
Medicine Name
Zepatier
Aliases
N/ANo risk management plan link.
